Pharsight

Drugs that contain Eribulin Mesylate

1. Halaven patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865

(Pediatric)

EISAI INC Macrocyclic analogs and methods of their use and preparation
Jan, 2024

(a month ago)

USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jan, 2027

(2 years from now)

USRE46965

(Pediatric)

EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jul, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage

HALAVEN family patents

Family Patents